GlobeNewswire Inc.··Coloplast A/SColoplast Slashes Growth Outlook as Kerecis Struggles Post-Medicare Changes
Coloplast cuts FY 2025/26 guidance citing Kerecis underperformance following Medicare reimbursement changes, taking DKK 3B impairment charge.
CLPBYorganic growthwound care